PDF(Pubmed)
Abstract：
Skeletal diseases impose a considerable burden on society. The clinical and tissue-engineering therapies applied to alleviate such diseases frequently result in complications and are inadequately effective. Research has shifted from conventional therapies based on mesenchymal stem cells (MSCs) to exosomes derived from MSCs. Exosomes are natural nanocarriers of endogenous DNA, RNA, proteins, and lipids and have a low immune clearance rate and good barrier penetration and allow targeted delivery of therapeutics. MSC-derived exosomes (MSC-exosomes) have the characteristics of both MSCs and exosomes, and so they can have both immunosuppressive and tissue-regenerative effects. Despite advances in our knowledge of MSC-exosomes, their regulatory mechanisms and functionalities are unclear. Here we review the therapeutic potential of MSC-exosomes for skeletal diseases.
摘要：
骨骼疾病给社会带来了相当大的负担。用于缓解此类疾病的临床和组织工程疗法经常导致并发症并且效果不充分。研究已经从基于间充质干细胞(MSC)的常规疗法转变为源自MSC的外泌体。外来体是内源性DNA的天然纳米载体,RNA,蛋白质，和脂质，并具有低的免疫清除率和良好的屏障渗透，并允许靶向递送治疗剂。MSC来源的外泌体(MSC-exosomes)同时具有MSC和外泌体的特性,因此它们可以同时具有免疫抑制和组织再生作用。尽管我们对MSC外泌体的认识有了进展，其调节机制和功能尚不清楚.在这里，我们回顾了MSC外泌体对骨骼疾病的治疗潜力。
